Morristown Medical Center: Leading Edge Research in CAR-T and TIL therapy
Morristown Medical Center now offers patients access to innovative clinical trials for immunotherapies including the use of Chimeric Antigen Receptor T Cells (CAR-T) and Tumor Infiltrating Lymphocytes (TIL).
Clinical Scorecard: Morristown Medical Center: Leading Edge Research in CAR-T and TIL therapy
At a Glance
Category Detail
Condition Blood cancers including leukemia, lymphoma, and myeloma Key Mechanisms Chimeric Antigen Receptor T Cells (CAR-T) and Tumor Infiltrating Lymphocytes (TIL) therapies Target Population Patients undergoing intensive chemotherapy or immunotherapy for blood cancers Care Setting Beckman Advanced Cellular Therapy Unit
Key Highlights
Access to innovative clinical trials for CAR-T and TIL therapies Creation of the Beckman Advanced Cellular Therapy Unit for enhanced patient care State-of-the-art hemodynamic monitoring technology Highly trained nursing staff for safe treatment delivery Commitment to expanding treatments to new cancers Guideline-Based Recommendations
Diagnosis
Monitor patients for treatment-related side effects Management
Utilize CAR-T and TIL therapies for eligible blood cancer patients Monitoring & Follow-up
Employ advanced monitoring technology in treatment settings Risks
Heightened vulnerability to treatment-related side effects in patients Patient & Prescribing Data
Patients with blood cancers receiving intensive therapies
Focus on providing the latest advancements in immunotherapy
Clinical Best Practices
Ensure access to advanced cellular therapies in specialized units Maintain a high level of nursing expertise in administering complex treatments Commit to ongoing research and development in cancer therapies References
